Developer docs
API playgroundTry for free, no card

Search company profiles

The Stevanato Group

Full company profile

uuid0000f12

Namestring
The Stevanato Group
Legal namestring
Stevanato Group S.p.A.
Company typeenum
Public
Founded yearint
1949
Descriptiontext

Stevanato Group S.p.A. (NYSE: STVN) is a vertically integrated Italian pharmaceutical packaging manufacturer founded in 1949 in Piombino Dese, Italy. The company produces glass primary packaging — vials, syringes, cartridges, and ampoules — alongside proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system. Its flagship EZ-fill® platform provides pre-sterilized, ready-to-use containers that eliminate in-house washing and sterilization steps for pharmaceutical customers, with the platform licensed to multiple competitors including Gerresheimer and SGD Pharma, establishing it as an industry standard.

The company's revenue is generated across five streams: Drug Containment Solutions (vials, syringes, cartridges, ampoules in bulk and RTU formats — the core business, with high-value solutions at ~47-49% of revenue); Drug Delivery Systems (proprietary devices and contract manufacturing, driven by GLP-1 demand); Engineering (glass converting equipment, visual inspection, assembly, packaging, serialization — a lower-margin segment experiencing recent declines); In-Vitro Diagnostics & Medical Solutions; and Analytical & Testing Services through SG Lab. Stevanato serves global pharmaceutical, biotechnology, and life sciences companies on a direct enterprise field sales basis, with particular focus on biologics/mAbs, GLP-1/incretin therapies, vaccines, RNA-based drugs, and antibody-drug conjugates.

The company operates nine production plants across Italy, Denmark, Slovakia, Mexico, China, Brazil, the United States, Germany, and Romania, with 4,000+ employees and a backlog supporting revenue visibility. FY2025 revenue reached €1.186 billion (~7% YoY growth, 9% constant currency) with adjusted EBITDA margin of 25.1%, and management guides to €1.26-1.29 billion in FY2026. The business model is B2B direct sales with quote/procurement-based pricing to pharmaceutical manufacturers, anchored by long regulatory validation cycles that create switching costs.

Short descriptiontext

Stevanato Group (NYSE: STVN) is a vertically integrated Italian manufacturer of glass primary packaging (vials, syringes, cartridges, ampoules) and proprietary drug delivery devices (autoinjectors, pen injectors, on-body systems) serving global pharmaceutical, biotechnology, and life sciences companies through direct enterprise sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersPiombino Dese, Italy
HQ citystring
Piombino Dese
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical glass packaging, drug containment solutions, drug delivery devices, pharmaceutical inspection systems, pharmaceutical manufacturing equipment
Industry5 codes
PRIMARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
SECONDARYIMALAEAB
Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)
SECONDARYIMANAEAK
Pharmaceutical & Medical Plastic Packaging Manufacturing
NAICS code3 codes
  • Glass Container Manufacturing327213
  • Surgical Appliance and Supplies Manufacturing339113
  • Glass and Glass Product Manufacturing3272
SIC code2 codes
  • Glass Containers3221
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pharmaceutical Packaging
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Drug Containment Solutions
TypeHardware Sales
Description

Glass primary packaging including vials, syringes, cartridges, and ampoules for pharmaceutical use, both in bulk and sterile RTU formats. This is the core revenue driver, with high-value solutions (HVS) comprising approximately 47-49% of total revenue. Includes proprietary EZ-fill platforms.

stevanatogroup.com
2Drug Delivery Systems
TypeHardware Sales
Description

Proprietary devices including pen injectors (Alina®, Deora™), autoinjectors (Aidaptus®), and on-body delivery systems (Vertiva®), along with contract manufacturing of drug delivery devices. Growing segment driven by GLP-1 and incretin-based therapies.

stevanatogroup.com
3Engineering Segment
TypeHardware Sales
Description

Equipment and technology for glass conversion, visual inspection, assembly, packaging, and serialization for pharmaceutical manufacturing. Includes after-sales services and support. Lower margin segment experiencing recent declines.

stevanatogroup.com
4In-Vitro Diagnostics & Medical Solutions
TypeHardware Sales
Description

Point-of-care devices, IVD consumables, and medical solutions including customer-specific developments.

stevanatogroup.com
5Analytical & Testing Services
TypeProfessional Services
Description

Chemical analysis, container interaction studies, surface characterization, container performance testing, drug delivery systems testing, and R&D fill-finish services through SG Lab.

stevanatogroup.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1EZ-fill
Description

Pre-sterilized drug containment solutions platform including vials, syringes, and cartridges that reduce total cost of ownership and time-to-market

stevanatogroup.com
+10 more records
Core offering1 text field

Stevanato Group manufactures and supplies integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. Its offerings span glass primary packaging (vials, syringes, cartridges, ampoules) under proprietary platforms such as EZ-fill®, EZ-fill Smart®, Alba®, Nexa® and Fina®; proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system; AI-powered visual inspection equipment and glass converting machinery; plus analytical and testing services through SG Lab.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • High-Value Solutions (HVS) segment grew 17% year-over-year to €128.6 million in Q1 2026, comprising 47% of group sales
+7 more records
Product overview1 text field

Stevanato Group is a leading global provider of integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. The company operates across two main divisions: Pharmaceutical Systems (drug containment and delivery) and Engineering Systems (equipment and inspection). The product portfolio centers on glass primary packaging (vials, syringes, cartridges, ampoules) across platforms including EZ-fill®, EZ-fill Smart®, Alba®, Nexa®, and Fina®, combined with drug delivery devices (Aidaptus® autoinjector, Alina® and Deora™ pen injectors, Vertiva® on-body system), visual inspection systems with AI-powered defect detection, glass converting equipment, device assembly lines, and comprehensive analytical/testing services. The company delivers an integrated, end-to-end offering from drug containment to delivery systems and quality assurance.

Product and service1 record
1EZ-fill® Platform (including EZ-fill Smart® and EZ-fill® Kit variants)
Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-09-16
Description

Joint presentation at PDA Japan Combination Product Seminar 2026 on 'Optimizing injectability of high-viscosity biologics in next-generation syringe-based autoinjectors', with speakers from both Stevanato Group and Ypsomed.

2Datwyler
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-16
Description

Three-way collaboration with Datwyler and LTS Device Technologies to expand large-volume subcutaneous drug delivery, combining Datwyler's NeoFlex plungers, Stevanato's EZ-fill Large Volume Cartridges, and LTS's Sorrel wearable delivery platform into a pre-verified ecosystem for at-home administration of high-dose therapies (up to 20mL) including monoclonal antibodies and oncology drugs. Showcased at Pharmapack Paris in January 2026. Driven by patient preference data showing 73% favor at-home self-administration after 24 weeks of therapy.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-16
Description

Three-way collaboration enabling on-body self-administration of large-volume drugs up to 20mL by combining LTS's Sorrel wearable delivery platform with Stevanato's EZ-fill Large Volume Cartridges and Datwyler's NeoFlex plungers. Addresses growing demand for at-home biologic treatments with pre-verified platform solution aimed at accelerating pharmaceutical manufacturers' market access.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

Collaborative session at CPHI 2025 featuring Gerresheimer and Stevanato Group joint capabilities, highlighting synergies in RTU potential, primary packaging innovations, and scalable fill-finish solutions. Gerresheimer showcased products including the EZ-fill Smart RTU platform and Gx InPuls on-body device.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-01-26
Description

Extended licensing agreement for Axis-D pen injector technology giving Stevanato Group exclusivity to offer the technology for a broader range of therapeutic areas beyond diabetes, including obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorders, and arthritis. Basis for Alina® pen injector platform.

6Corning Incorporated
Strategic tierStrategicTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-07-26
Description

Collaboration agreement for supply of Corning Valor Glass—an enhanced pharmaceutical glass with superior chemical durability, strength, and damage resistance. Valor Glass addresses modern drug formulations and manufacturing processes, providing stronger and more chemically durable packaging to better protect drug products including life-saving medicines and vaccines.

ir.stevanatogroup.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2017-03-14
Description

Partnership agreement for extractables and leachables analysis services. SG Lab combines its glass testing, physical testing, and container/closure integrity testing capabilities with Toxikon's expertise in extractables & leachables testing, toxicological assessments, and biocompatibility testing. Provides pharmaceutical companies with comprehensive analytical services for regulatory compliance across FDA and EMA requirements.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2017-03-09
Description

License agreement making Gerresheimer a partner on the Ompi EZ-fill® platform, reaffirming EZ-fill as the worldwide proven standard in processing sterile glass vials and cartridges. This validates the EZ-fill platform and extends its reach through Gerresheimer's global distribution network.

Strategic tierStrategicTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-31
Description

Licensing agreement for safety needlestick protection platform technology enabling Ompi EZ-fill® ISS (Integrated Safety System) for prefilled syringes. The safety system prevents needlestick injury post-injection through a passive locking mechanism. All plastic components are designed and produced by Balda, a Stevanato Group company.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2016-02-10
Description

SGD Pharma became the first molded glass supplier to join the Ompi EZ-fill® platform, offering sterile and depyrogenated RTU molded vials. Validates EZ-fill as a platform standard extending beyond Stevanato's own products.

Recent move15 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-headquartered global manufacturer of pharmaceutical glass and plastic packaging plus drug delivery devices; a direct competitor in primary packaging and an EZ-fill® licensee.

TypeDirect peer
Description

Subsidiary of SCHOTT AG and leading producer of pharmaceutical glass vials, syringes, cartridges, and ampoules; competes head-to-head with Stevanato in primary containment for injectables.

TypeDirect peer
Description

French manufacturer of molded and tubular glass pharmaceutical packaging; joined the EZ-fill® platform as the first molded-glass licensee, making it both a partner and direct competitor.

TypeBroad incumbent
Description

US-based global leader in elastomeric closures, seals, and drug delivery components for injectables; competes with Stevanato's containment and delivery offering from an adjacent, broader component portfolio.

TypeDirect peer
Description

Swiss manufacturer of injection systems (pen injectors and autoinjectors) and a direct Stevanato co-development partner via joint presentations on high-viscosity biologics autoinjectors.

TypeBroad incumbent
Description

US-based global supplier of drug delivery devices, dispensing closures, and active material solutions; competes in elastomeric/injectable delivery components and broader pharma packaging.

TypeBroad incumbent
Description

Global medical technology incumbent with a large pharmaceutical systems segment offering prefilled syringes, drug delivery devices, and injection systems; overlaps with Stevanato across containment and delivery.

8Corning Incorporated
TypeBroad incumbent
Description

Supplier of Corning Valor Glass to Stevanato under collaboration agreement; also a broader competitor in pharmaceutical glass with deep US manufacturing footprint and direct federal relationships.

9Dätwyler Holding AG
TypeDirect peer
Description

Swiss manufacturer of elastomer components and plunger/seal systems for injectable drug packaging; a Stevanato partner on EZ-fill® Large Volume Cartridge ecosystems (NeoFlex plungers).

10Nipro Corporation
TypeDirect peer
Description

Japanese medical device and pharmaceutical glass manufacturer producing glass tubing, vials, syringes, and dialyzers; competes directly with Stevanato in primary packaging for injectables, particularly in Asia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature15 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Stevanato Group

Pharmaceutical Packagingstevanatogroup.com

Stevanato Group (NYSE: STVN) is a vertically integrated Italian manufacturer of glass primary packaging (vials, syringes, cartridges, ampoules) and proprietary drug delivery devices (autoinjectors, pen injectors, on-body systems) serving global pharmaceutical, biotechnology, and life sciences companies through direct enterprise sales.

What The Stevanato Group does

Stevanato Group S.p.A. (NYSE: STVN) is a vertically integrated Italian pharmaceutical packaging manufacturer founded in 1949 in Piombino Dese, Italy. The company produces glass primary packaging — vials, syringes, cartridges, and ampoules — alongside proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system. Its flagship EZ-fill® platform provides pre-sterilized, ready-to-use containers that eliminate in-house washing and sterilization steps for pharmaceutical customers, with the platform licensed to multiple competitors including Gerresheimer and SGD Pharma, establishing it as an industry standard.

The company's revenue is generated across five streams: Drug Containment Solutions (vials, syringes, cartridges, ampoules in bulk and RTU formats — the core business, with high-value solutions at ~47-49% of revenue); Drug Delivery Systems (proprietary devices and contract manufacturing, driven by GLP-1 demand); Engineering (glass converting equipment, visual inspection, assembly, packaging, serialization — a lower-margin segment experiencing recent declines); In-Vitro Diagnostics & Medical Solutions; and Analytical & Testing Services through SG Lab. Stevanato serves global pharmaceutical, biotechnology, and life sciences companies on a direct enterprise field sales basis, with particular focus on biologics/mAbs, GLP-1/incretin therapies, vaccines, RNA-based drugs, and antibody-drug conjugates.

The company operates nine production plants across Italy, Denmark, Slovakia, Mexico, China, Brazil, the United States, Germany, and Romania, with 4,000+ employees and a backlog supporting revenue visibility. FY2025 revenue reached €1.186 billion (~7% YoY growth, 9% constant currency) with adjusted EBITDA margin of 25.1%, and management guides to €1.26-1.29 billion in FY2026. The business model is B2B direct sales with quote/procurement-based pricing to pharmaceutical manufacturers, anchored by long regulatory validation cycles that create switching costs.

The Stevanato Group firmographics

Firmographics
Name
The Stevanato Group
Legal name
Stevanato Group S.p.A.
Website
https://stevanatogroup.com
Company type
Public
Founded year
1949
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Stevanato Group (NYSE: STVN) is a vertically integrated Italian manufacturer of glass primary packaging (vials, syringes, cartridges, ampoules) and proprietary drug delivery devices (autoinjectors, pen injectors, on-body systems) serving global pharmaceutical, biotechnology, and life sciences companies through direct enterprise sales.
Ownership category
akta.pro rank

The Stevanato Group industry classification

Industry
Product category
Pharmaceutical Packaging
NAICS
Glass Container Manufacturing (327213), Surgical Appliance and Supplies Manufacturing (339113), Glass and Glass Product Manufacturing (3272)
SIC
Glass Containers (3221), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
SECONDARYIMALAEAB
Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)
SECONDARYIMANAEAK
Pharmaceutical & Medical Plastic Packaging Manufacturing

Keywords

  • Pharmaceutical glass packaging
  • Drug containment solutions
  • Drug delivery devices
  • Pharmaceutical inspection systems
  • Pharmaceutical manufacturing equipment

Where The Stevanato Group is headquartered

Location

Headquarters

HQ city
Piombino Dese
HQ country
Italy
HQ region
Europe

Offices12 records

Markets served

The Stevanato Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Drug Containment Solutions: Glass primary packaging including vials, syringes, cartridges, and ampoules for pharmaceutical use, both in bulk and sterile RTU formats. This is the core revenue driver, with high-value solutions (HVS) comprising approximately 47-49% of total revenue. Includes proprietary EZ-fill platforms.
  2. Drug Delivery Systems: Proprietary devices including pen injectors (Alina®, Deora™), autoinjectors (Aidaptus®), and on-body delivery systems (Vertiva®), along with contract manufacturing of drug delivery devices. Growing segment driven by GLP-1 and incretin-based therapies.
  3. Engineering Segment: Equipment and technology for glass conversion, visual inspection, assembly, packaging, and serialization for pharmaceutical manufacturing. Includes after-sales services and support. Lower margin segment experiencing recent declines.
  4. In-Vitro Diagnostics & Medical Solutions: Point-of-care devices, IVD consumables, and medical solutions including customer-specific developments.
  5. Analytical & Testing Services: Chemical analysis, container interaction studies, surface characterization, container performance testing, drug delivery systems testing, and R&D fill-finish services through SG Lab.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

The Stevanato Group product offering

Product offering

Core offering

Stevanato Group manufactures and supplies integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. Its offerings span glass primary packaging (vials, syringes, cartridges, ampoules) under proprietary platforms such as EZ-fill®, EZ-fill Smart®, Alba®, Nexa® and Fina®; proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system; AI-powered visual inspection equipment and glass converting machinery; plus analytical and testing services through SG Lab.

Product overview

Stevanato Group is a leading global provider of integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. The company operates across two main divisions: Pharmaceutical Systems (drug containment and delivery) and Engineering Systems (equipment and inspection). The product portfolio centers on glass primary packaging (vials, syringes, cartridges, ampoules) across platforms including EZ-fill®, EZ-fill Smart®, Alba®, Nexa®, and Fina®, combined with drug delivery devices (Aidaptus® autoinjector, Alina® and Deora™ pen injectors, Vertiva® on-body system), visual inspection systems with AI-powered defect detection, glass converting equipment, device assembly lines, and comprehensive analytical/testing services. The company delivers an integrated, end-to-end offering from drug containment to delivery systems and quality assurance.

Differentiator

Problem solved

Functional benefit

Brands

  • EZ-fill: Pre-sterilized drug containment solutions platform including vials, syringes, and cartridges that reduce total cost of ownership and time-to-market
  • EZ-fill Smart
  • Nexa
  • Alba
  • Fina
  • Aidaptus
  • Alina
  • Deora
  • Vertiva
  • SG Lab
  • Ompi EZ-fill

Products and services

  • EZ-fill® Platform (including EZ-fill Smart® and EZ-fill® Kit variants)

Quantifiable outcome

  • High-Value Solutions (HVS) segment grew 17% year-over-year to €128.6 million in Q1 2026, comprising 47% of group sales
  • +7 more outcomes

Companies that use The Stevanato Group

Customer profile

Named customers3 records

Segments6 records

Ideal customer profiles3 records

The Stevanato Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature15 records

The Stevanato Group partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor, core and strategic.

  • Ypsomed AGminorStrategic or Co-development Partner · 16 September 2026Joint presentation at PDA Japan Combination Product Seminar 2026 on 'Optimizing injectability of high-viscosity biologics in next-generation syringe-based autoinjectors', with speakers from both Stevanato Group and Ypsomed.
  • DatwylercoreStrategic or Co-development Partner · 16 January 2026Three-way collaboration with Datwyler and LTS Device Technologies to expand large-volume subcutaneous drug delivery, combining Datwyler's NeoFlex plungers, Stevanato's EZ-fill Large Volume Cartridges, and LTS's Sorrel wearable delivery platform into a pre-verified ecosystem for at-home administration of high-dose therapies (up to 20mL) including monoclonal antibodies and oncology drugs. Showcased at Pharmapack Paris in January 2026. Driven by patient preference data showing 73% favor at-home self-administration after 24 weeks of therapy.
  • LTS Device TechnologiescoreStrategic or Co-development Partner · 16 January 2026Three-way collaboration enabling on-body self-administration of large-volume drugs up to 20mL by combining LTS's Sorrel wearable delivery platform with Stevanato's EZ-fill Large Volume Cartridges and Datwyler's NeoFlex plungers. Addresses growing demand for at-home biologic treatments with pre-verified platform solution aimed at accelerating pharmaceutical manufacturers' market access.
  • Gerresheimer AGstrategicStrategic or Co-development Partner · 28 October 2025Collaborative session at CPHI 2025 featuring Gerresheimer and Stevanato Group joint capabilities, highlighting synergies in RTU potential, primary packaging innovations, and scalable fill-finish solutions. Gerresheimer showcased products including the EZ-fill Smart RTU platform and Gx InPuls on-body device.
  • Haselmeier (medmix group)coreOEM/ Whitelabel/ Licensing Partner · 26 January 2022Extended licensing agreement for Axis-D pen injector technology giving Stevanato Group exclusivity to offer the technology for a broader range of therapeutic areas beyond diabetes, including obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorders, and arthritis. Basis for Alina® pen injector platform.
  • Corning IncorporatedstrategicOEM/ Whitelabel/ Licensing Partner · 26 July 2017Collaboration agreement for supply of Corning Valor Glass—an enhanced pharmaceutical glass with superior chemical durability, strength, and damage resistance. Valor Glass addresses modern drug formulations and manufacturing processes, providing stronger and more chemically durable packaging to better protect drug products including life-saving medicines and vaccines.
  • Toxikon EuropestrategicStrategic or Co-development Partner · 14 March 2017Partnership agreement for extractables and leachables analysis services. SG Lab combines its glass testing, physical testing, and container/closure integrity testing capabilities with Toxikon's expertise in extractables & leachables testing, toxicological assessments, and biocompatibility testing. Provides pharmaceutical companies with comprehensive analytical services for regulatory compliance across FDA and EMA requirements.
  • Gerresheimer AGstrategicTechnology or Integration · 9 March 2017License agreement making Gerresheimer a partner on the Ompi EZ-fill® platform, reaffirming EZ-fill as the worldwide proven standard in processing sterile glass vials and cartridges. This validates the EZ-fill platform and extends its reach through Gerresheimer's global distribution network.
  • Tip-TopstrategicOEM/ Whitelabel/ Licensing Partner · 31 January 2017Licensing agreement for safety needlestick protection platform technology enabling Ompi EZ-fill® ISS (Integrated Safety System) for prefilled syringes. The safety system prevents needlestick injury post-injection through a passive locking mechanism. All plastic components are designed and produced by Balda, a Stevanato Group company.
  • SGD PharmastrategicTechnology or Integration · 10 February 2016SGD Pharma became the first molded glass supplier to join the Ompi EZ-fill® platform, offering sterile and depyrogenated RTU molded vials. Validates EZ-fill as a platform standard extending beyond Stevanato's own products.

Scale indicators19 records

Recent moves15 records

Expansion highlights6 records

The Stevanato Group competitors and assessment

Company assessment

Direct peers

  • Gerresheimer AG: German-headquartered global manufacturer of pharmaceutical glass and plastic packaging plus drug delivery devices; a direct competitor in primary packaging and an EZ-fill® licensee.
  • SCHOTT Pharma AG & Co. KGaA: Subsidiary of SCHOTT AG and leading producer of pharmaceutical glass vials, syringes, cartridges, and ampoules; competes head-to-head with Stevanato in primary containment for injectables.
  • SGD Pharma: French manufacturer of molded and tubular glass pharmaceutical packaging; joined the EZ-fill® platform as the first molded-glass licensee, making it both a partner and direct competitor.
  • Ypsomed AG: Swiss manufacturer of injection systems (pen injectors and autoinjectors) and a direct Stevanato co-development partner via joint presentations on high-viscosity biologics autoinjectors.
  • Dätwyler Holding AG: Swiss manufacturer of elastomer components and plunger/seal systems for injectable drug packaging; a Stevanato partner on EZ-fill® Large Volume Cartridge ecosystems (NeoFlex plungers).
  • Nipro Corporation: Japanese medical device and pharmaceutical glass manufacturer producing glass tubing, vials, syringes, and dialyzers; competes directly with Stevanato in primary packaging for injectables, particularly in Asia.

Broad incumbents

  • West Pharmaceutical Services: US-based global leader in elastomeric closures, seals, and drug delivery components for injectables; competes with Stevanato's containment and delivery offering from an adjacent, broader component portfolio.
  • AptarGroup, Inc. US-based global supplier of drug delivery devices, dispensing closures, and active material solutions; competes in elastomeric/injectable delivery components and broader pharma packaging.
  • Becton, Dickinson and Company (BD): Global medical technology incumbent with a large pharmaceutical systems segment offering prefilled syringes, drug delivery devices, and injection systems; overlaps with Stevanato across containment and delivery.
  • Corning Incorporated: Supplier of Corning Valor Glass to Stevanato under collaboration agreement; also a broader competitor in pharmaceutical glass with deep US manufacturing footprint and direct federal relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

The Stevanato Group social profiles

Digital presence

The Stevanato Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Stevanato Group leadership team

Management profile

Number of profiles

Profiles12 records

The Stevanato Group subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

The Stevanato Group funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Stevanato Group M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Stevanato Group

What does The Stevanato Group do?

Stevanato Group manufactures and supplies integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. Its offerings span glass primary packaging (vials, syringes, cartridges, ampoules) under proprietary platforms such as EZ-fill®, EZ-fill Smart®, Alba®, Nexa® and Fina®; proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system; AI-powered visual inspection equipment and glass converting machinery; plus analytical and testing services through SG Lab.

Is The Stevanato Group a public or private company?

The Stevanato Group is a public company. It is classified as public and is currently operating.

When was The Stevanato Group founded?

The Stevanato Group was founded in 1949. It employs 1,001 to 5,000 people.

Where is The Stevanato Group based?

The Stevanato Group is headquartered in Piombino Dese, Italy, in the Europe region.

How does The Stevanato Group make money?

Five revenue lines are on record. Drug Containment Solutions are the primary driver. The others are drug Delivery Systems, engineering Segment, in-Vitro Diagnostics & Medical Solutions and analytical & Testing Services.

Who are The Stevanato Group's main competitors?

Direct peers on record are Gerresheimer AG, SCHOTT Pharma AG & Co. KGaA, SGD Pharma, Ypsomed AG, Dätwyler Holding AG and Nipro Corporation. Broad incumbents are West Pharmaceutical Services, AptarGroup, Inc., Becton, Dickinson and Company (BD) and Corning Incorporated.

Does The Stevanato Group have an API?

No public API is recorded for The Stevanato Group.

What industry is The Stevanato Group in?

The Stevanato Group's product category is Pharmaceutical Packaging. Its primary akta.pro industry code is IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules), with a secondary code of IMALAEAB, Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes). Its NAICS code is 327213 and its SIC code is 3221.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsStevanato Group S.p.A. $STVN Stock: CenterBook Partners LP Trims StakeCenterBook Partners LP cut its stake in Stevanato Group by 69.2% in Q3, selling 60,425 shares. Insider Mauro Stocchi sold 13,649 shares, while director Donald Morel bought 25,000. Analysts' consensus is a Moderate Buy, with UBS lowering its price target to $16.Investing.comWhy is SCHOTT Pharma stock sliding today?SCHOTT Pharma shares fell 6.2% to €20.40 after UBS downgraded the drug packaging maker from Buy to Neutral and cut its price target to €22.30. RBC Capital Markets also downgraded the stock, citing declining glass syringe demand and Stevanato's lower GLP-1 syringe volume outlook. The stock traded near its session low of €20.30, well below its 52-week high of €26.20.Business Wire BlogSTVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS LawSchall, Brown & Schwartz LLP is investigating Stevanato Group S.p.A. for securities law violations, focusing on false or misleading statements. The investigation follows Q3 2026 results showing GLP-1 revenue fell to about 18% of total revenue, causing shares to drop nearly 28.6%.FinancialContent Business PageSTVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS LawSchall, Brown & Schwartz LLP is investigating Stevanato Group S.p.A. for securities law violations, focusing on false or misleading statements. The company's Q3 2026 GLP-1 revenue fell to about 18% of total revenue, and shares dropped nearly 28.6% on the same day. SBS invites affected shareholders to contact the firm for free legal advice.Simply Wall StEarnings Release: Here's Why Analysts Cut Their Stevanato Group S.p.A. (NYSE:STVN) Price Target To US$22.04Stevanato Group's Q3 statutory earnings missed estimates by 3.9% at €0.15 per share, while revenue of €326m was on track. Analysts cut their consensus price target to $22.04, with 2027 EPS forecasts down to €0.64. The company's revenue growth is expected to slow to 5.1% annually, below the industry's 7.0%.Defense WorldStevanato Group (NYSE:STVN) Price Target Cut to $16.00 by Analysts at UBS GroupUBS cut its price target on Stevanato Group from $23 to $16, keeping a neutral rating. The company reported Q3 EPS of €0.16, missing the €0.17 consensus, while revenue rose 8% to €326.06 million. Management expects low-single-digit growth in 2027.American Banking and Market NewsStevanato Group S.p.A. $STVN Stock: Conestoga Capital Advisors LLC Decreases PositionConestoga Capital Advisors LLC cut its stake in Stevanato Group by 20.1% in Q3, selling 1.41 million shares. The firm now holds 5.59 million shares, about 1.85% of the company. Stevanato reported Q3 revenue of €326.1 million, up 8% year-over-year.TradingViewWilliam Blair downgrades Stevanato Group to Market Perform from OutperformWilliam Blair downgraded Stevanato Group to Market Perform from Outperform. The rating change is reported without additional details on the rationale or price target.GlobeNewswireSTVN INVESTOR ALERT: Investigation of Stevanato Group S.p.A. Announced by Holzer & Holzer, LLCHolzer & Holzer, LLC announced an investigation into Stevanato Group S.p.A. over compliance with federal securities laws. The firm cited a Q3 2026 earnings call where GLP-1 revenue was disclosed as 17-18% of total revenue, causing a stock drop. The alert encourages affected investors to contact the firm.FinancialContent Business PageLost Money on Stevanato Group S.p.A. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 28.57% Share Price DropGlancy Prongay Wolke & Rotter LLP announced a securities fraud investigation into Stevanato Group S.p.A. after its stock fell 28.57% on November 3, 2026, following a disclosure that GLP-1 revenue dropped to 17-18% of total revenue and 2027 growth was expected to be low single-digit. Investors who lost money may have claims to recover their losses.